Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(12.31) per share which beat the analyst consensus estimate of $(26.32) by 53.21 percent. This is a 81.9 percent increase over losses of $(68.00) per share from the same period last year.